



Practitioner's Docket No. **MPI03-043PIRNM**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Hepperle, Michael E., et al.		
Application No.:	10/821,545	Group No.:	1614
Filed:	April 9, 2004	Examiner:	Not Yet assigned
For:	BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement submitted herewith is being filed:
☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ *After* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker/Beverly Sotiropoulos

(type or print name of person certifying)

Date: November 23, 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. **MP103-043P1RNM**

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☒ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

FEE PAYMENT

2. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

METHOD OF PAYMENT OF FEE

3. ☐ Attached is a check in the amount of \$ _____ .
☐ Charge Account No. 501668 in the amount of \$0.00 .
☐ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

November 23, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By *Ian Robert Silverman*
Ian Robert Silverman
Attorney Applicant
Reg. No. 37,443
40 Landsdowne Street
Cambridge, MA 02139
Telephone: (617) 551-8604
Facsimile - (617) 551-8820

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/821,545
				Filing Date	April 9, 2004
				First Named Inventor	Michael E. Hepperle
				Group Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	Attorney Docket Number	MP103- 043P1RNM	1	Attorney Docket Number	MP102-162P1RM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.			T ²
/K.B./	C1	CASTRO, Alfredo C. et al., "Novel IKK Inhibitors: β -Carbolines," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 13, No. 14 (2003), pp 2419-2422			
/K.B./	C2	HOTTELET, M. et al., "Development of I κ B Kinase Inhibitors as Anti-Inflammatory Therapeutics," <i>Inflammation Research</i> , Birkhaeuser Verlag, Vol. 49, No. Supplement 2 (Sept. 24, 2000), p S91 (Abstract)			
/K.B./	C3	LEE, Michael et al., "Down-Regulation of Protein Kinase C in Murine Splenocytes: A Potential Mechanism for 2-Acetylaminofluorene-Mediated Immunosuppression," <i>Cancer Letters</i> , Vol. 101, No. 1 (1996), pp 53-57			
/K.B./	C4	PALANKI, Moorthy S.S., "Inhibitors of AP-1 and NF- κ B Mediated Transcriptional Activation Therapeutic Potential in Autoimmune Diseases and Structural Diversity," <i>Current Medicinal Chemistry</i> , Vol. 9, No. 2 (Jan. 2002), pp 219-227			
Examiner Signature	/Kristin Bianchi/			Date Considered	08/20/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.